PubMed Health⌕ Search

Biomedical subjects

M C Lueg

Publications and source records attributed to M C Lueg.

14 recordsLinked to original sources
PubMed1993

A clinical trial evaluating the 24-hour effects of bisoprolol/hydrochlorothiazide 5 mg/6.25 mg combination in patients with mild to moderate hypertension.

This study used 24-h ambulatory blood pressure (BP) monitoring to investigate the effectiveness of a novel low-dose combination of bisoprolol/hydrochlorothiazide in adult patients with mild to moderate essential hypertension. Thirty-six patients with stable mild to moderate hypertension (sitting diastolic BP 95-114 mmHg) after a placebo run-in phase received oral bisoprolol/hydrochlorothiazide 5 mg/6.25 mg once daily for 4 weeks in a single-blind regimen. At office visits, BP and pulse were measured with statistically significant reductions (p < 0.01) recorded after 2 and 4 weeks of treatment. Twenty-four-h ambulatory BP monitoring at the completion of therapy revealed significant reductions (p < 0.01) in both systolic and diastolic 24-h, daytime, and nighttime BP, compared with the end of the placebo treatment phase. Systolic and diastolic load were also reduced (p < 0.01). The combination was well tolerated, and overall quality-of-life questionnaire scores indicated an improvement after bisoprolol/hydrochlorothiazide therapy (p = 0.02). No clinically significant changes from baseline in laboratory parameters were observed; in particular, serum potassium was unchanged. This is the first study to demonstrate the 24-h effectiveness of the bisoprolol/hydrochlorothiazide 5 mg/6.25 mg combination, using 24-h ambulatory BP monitoring. In addition, antihypertensive therapy with low doses of bisoprolol/hydrochlorothiazide in combination may improve tolerability.

Bisoprolol↗
PubMed1988

Postmenopausal osteoporosis: treatment with low-dose sodium fluoride and estrogen.

Eleven menopausal patients were treated for 12 to 18 months with low-dose sodium fluoride and calcium. Six patients also received estrogen replacement. A significant increase in spine or hip bone mineral density measured by dual photon absorptiometry was observed in all patients. The estrogen-treated group had the greatest increase in bone density. Addition of estrogen seems to supplement bone gain and allow sodium fluoride to be administered in lower doses, which are easily tolerated and yet effective.

Aged↗
PubMed1983

Primary hyperparathyroidism and pregnancy.

The incidence of pregnancy with primary hyperparathyroidism (PHPT) is probably underestimated, possibly because of the lack of routine prenatal serum calcium screening and possibly because the combination of pregnancy and mild asymptomatic PHPT is less than disastrous. This is the first reported case in which serum calcium and parathyroid hormone levels were measured periodically during a successful gestation in an asymptomatic and untreated patient with provisional primary hyperparathyroidism.

Adenoma↗
PubMed1982

Hypertension and primary hyperparathyroidism: a five-year case review.

All cases of surgically proven and cured primary hyperparathyroidism, over a five-year period, were reviewed for the presence of hypertension, renal and/or prerenal azotemia, nephrolithiasis, nephrocalcinosis, and patient symptom status. In this group of 23 patients, the prevalence of hypertension was greater than 78% (18 patients), which is statistically significant. Approximately 28% (5 patients) of the 18 hypertensive patients had some degree of azotemia and/or elevated serum creatinine. Most of the 23 patients were symptomatic, over the age of 50, female, and without nephrolithiasis or nephrocalcinosis. The possible etiologic mechanisms of calcium-mediated hypertension are discussed, and the important association of hypertension with primary hyperparathyroidism is emphasized.

Adenoma↗
PubMedDate not supplied

Transdermal clonidine as an adjunct to sustained-release diltiazem in the treatment of mild-to-moderate hypertension.

An open-label study was conducted to evaluate the clinical safety and efficacy of transdermal clonidine as an adjunct to sustained-release (SR) diltiazem (90 mg twice daily) in mild-to-moderate hypertension. Ninety patients with a mean baseline sitting blood pressure of 154/102 mmHg were given 90 mg of diltiazem SR twice daily and transdermal placebo. After four weeks of therapy, 21 patients (23%) had trough sitting diastolic blood pressures (DBP) less than 90 mmHg and were withdrawn. Of the remaining 69 patients (DBP greater than or equal to 90 mmHg), 60 (mean blood pressure 149/98 mmHg) continued to receive 90 mg of diltiazem SR twice daily, to which was added transdermal clonidine, titrated as needed (3.5 cm2, 7.0 cm2, or 10.5 cm2) to achieve blood pressure control. During titration, 58 patients achieved DBP less than 90 mmHg, with a mean blood pressure of 133/84 mmHg. Of these patients, 54 completed an eight-week maintenance period, during which their mean blood pressure was 137/84 mmHg. No significant decrease in pulse or change from baseline in lipid profiles (high-density lipoprotein, low-density lipoprotein, apolipoprotein A-I, apolipoprotein B) was observed with combination therapy. The most frequently reported side effect during maintenance therapy was mild skin irritation at the transdermal application site. One patient was withdrawn because of contact dermatitis. Compliance with the oral twice-daily regimen was variable, with 83% of patients failing to take diltiazem SR at the prescribed dosing intervals 80% to 100% of the time. Transdermal clonidine was worn as directed by 97% of patients. It is concluded that transdermal clonidine in combination with diltiazem SR is safe and effective in the treatment of mild-to-moderate hypertension.

Administration, Cutaneous↗